| ||||||||||||||||
| ||||||||||||||||
— ImClone —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "ImClone." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "ImClone"Big PharmaPfizer-Wyeth, Merck-Schering Plough. 2009 has seen some big-ticket pharma deals. Carl IcahnBiogen, WCI, Tropicana ... another day, another company for activist investor Carl Icahn. Here's the latest. Dialoguing at DeutscheBruce Evans takes the reins of Deutsche's M&A effort at a difficult time. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Out of rhythmBoston Scientific snatched cardiac implant maker Guidant away from healthcare giant Johnson & Johnson three years ago and hasn't breathed easily since. They need a new drugExpect Big Pharma to go shopping in biotechland, but with an eye for fire sales. ImCloneMassachusetts' State-Boston Pension Fund has stepped in with a lawsuit to block Eli Lilly's $6.5 billion deal for ImClone. Spread too farAmid turmoil, risk arbs have absorbed a lot of bad news, but some strategic deals look likely to close, and deal demand may be building. Latham gilds Lilly's ImClone offerDeutsche Bank AG's Jim Stynes, Michael Cohen and Bruce Evans were among the financial advisers. Risk Arb updateUncertainty in banking and M&A credit markets have hammered share prices of targets of hostile bids, along with the broader stock market. Bristol taps Citi, Cravath for advice on ImCloneCitigroup, Morgan Stanley and Cravath advise Bristol as it pursues ImClone with a $4.5 billion offer. Carl Icahn, Icahn Enterprises chairmanIcahn's long career as an activist investor includes governance battles with RJR Nabisco, Viacom, Time Warner, Motorola and many other public companies. | ||||||||||||||||
|
|
|
|
|
